Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19
Status:
Completed
Trial end date:
2020-05-31
Target enrollment:
Participant gender:
Summary
The effective medical treatment against COVID-19 infection is still unknown. Chloroquine
phosphate is a well-known antimalarial drug which has been on the market for many years.
Recently, in vitro study shown that Chloroquine is effective at both entry and at post-entry
stages of the COVID-19 infection of Vero E6 cells with promising results. Chloroquine is also
an immune-modifier and could distribute to the whole body including lung. Also, chloroquine
is cheap and safe, and could be a promising agent against COVID-19 infection. However, only
hydroxychloroquine (HCQ) with the extra hydroxyl group is available in Taiwan. Therefore,
hydroxychloroquine instead become the best choice for the treatment candidate, since it shows
higher in vitro potency (EC50) against COVID-19 with lower toxicity while retaining the
original effect which compared with chloroquine.
Phase:
N/A
Details
Lead Sponsor:
Taoyuan General Hospital
Collaborators:
Center for Drug Evaluation, Taiwan Centers for Disease Control, Taiwan National Health Research Institutes, Taiwan Taiwan Food and Drug Administration